Companies: 10,795·Total market cap: $144.5T
Castle Biosciences, Inc.

Castle Biosciences, Inc.

CSTLNASDAQHealthcare● Active
$20.24
$-0.77(-3.66%)
Market Cap$613929789
P/E Ratio
52W High$44.28
52W Low$14.59
Overview

Castle Biosciences, Inc. (CSTL) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

cstl · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 11 Wall Street analysts in the past 3 months

SellBuy

Buy

11 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
11
Hold
0
Sell
0
Strong Sell
0
Total: 11 · Buy rate: 100.0%

12-Month Price Target

High

$52.00

Consensus

$44.80

+121.2% upside

Low

$35.00

Median: $47 · Last Close: $20.25

The Castle Biosciences, Inc. (CSTL) analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month CSTL price target is $44.80, representing +121.2% upside from the current price of $20.25.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $45 (121.2%)

Consensus Target

$44.80

121.2% upside

High Target

$52

156.8%

Low Target

$35

72.8%

Current Price

$20.25

as of today

Based on analyst price targets, the CSTL stock price prediction for the next 12 months ranges from $35 to $52. The consensus CSTL price forecast of $44.80 implies 121.2% upside from the current price of $20.25.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$20.712.26%

1-day model range: $20.45–$20.97. Peak: $20.97 (+2.26%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$23+14.3%
2028$25+23.3%
2029$26+28.6%
2030$27+31.7%
2031+33.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

7%7%86%
1Buy
1Neutral
12Sell
RSI (14)54.5Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · CSTL · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$20.59SELL
MA 10$20.81SELL
MA 20$20.06BUY
MA 50$22.52SELL
MA 100$27.36SELL
MA 200$28.76SELL
Current $CSTL · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$20.69SELL
EMA 10$20.67SELL
EMA 20$20.90SELL
EMA 50$22.77SELL
EMA 100$25.38SELL
EMA 200$26.59SELL
Current $CSTL · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
BTIG2026-05-13
Maintains
BuyBuy
Baird2026-05-07
Maintains
OutperformOutperform
Canaccord Genuity2026-04-20
Maintains
BuyBuy
Baird2026-02-27
Maintains
OutperformOutperform
Guggenheim2026-01-26
Maintains
BuyBuy
Lake Street2026-01-12
Maintains
BuyBuy
Guggenheim2026-01-05
Maintains
BuyBuy
Canaccord Genuity2025-12-22
Maintains
BuyBuy
BTIG2025-12-12
Maintains
BuyBuy
BTIG2025-11-05
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Castle Biosciences, Inc. (CSTL) stock. Of the recent 75 rating actions, 0 were upgrades and 0 were downgrades. 11 analysts currently cover CSTL.

Analyst Recommendation Trends

Buy ratings22
Hold ratings00
Sell ratings00

CSTL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$352M

↓ 18.9% YoY

Revenue Next Year

$393M

↑ 11.5% YoY

EPS This Year

$-1.45

EPS Next Year

$-0.93

↓ 36.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CSTL EPS of $-1.45 for the current fiscal year, based on estimates from 5 analysts. The CSTL revenue forecast is $352M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The CSTL stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CSTL price target is $44.80 (+121.2% upside), with an analyst consensus of Buy.

The CSTL short-term stock prediction for tomorrow is $20.71 (+2.26%). The CSTL stock price prediction for 2027 estimates an average of $23. The CSTL stock prediction for 2030 projects a range of $24–$30.

Castle Biosciences, Inc. trades on NASDAQ under the ticker CSTL. The CSTL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

CSTL forecast · 8 questions

According to 11 Wall Street analysts, the average 12-month CSTL price target is $44.80, with a high forecast of $52.00 and a low of $35.00. The median price target is shown in the chart above when available. This implies +121.2% potential upside from the current price of $20.25.

CSTL price targetWhat is CSTL price targetCSTL analyst price targetCSTL 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.